Table 3 of Hayashida, Mol Vis 2020; 26:505-509.

Table 3. Clinical outcomes of cCSC patients according to ARMS2 genotype.

BCVA (logMAR) ARMS2 (rs10490924) P value
GG GT + TT
baseline 0.12 ± 0.28 0.20 ± 0.26 0.15
12 months after RFPDT −0.022 ± 0.19 0.13 ± 0.27 <0.01

Values are presented as mean ± SD. cCSC, chronic central serous chorioretinopathy; RFPDT, reduced-fluence photodynamic therapy; BCVA, best-corrected visual acuity; logMAR, logarithmic minimum angle of resolution.

Hayashida, Mol Vis 2020; 26:505-509. http://www.molvis.org/molvis/v26/505

©2020 Molecular Vision http://www.molvis.org/molvis/

ISSN 1090-0535